I can't predict the stock price, but I can tell you the results were not bad, with p=.105 which means they are equivalent because its greater than .05 which means no hurdle to FDA approval compared to the preliminary results that could have been statistically different.
The FDA has approved drugs with far worse results, the study isn't good for marketing of the drug in regards to living longer, but it has enough advantages to be a strong alternative based on better quality of life. It is also possible that a combination of it with another treatment will be found to be effective. Yeh, the stock is tanking after hours, but the FDA approval is all that matters, and these results increased that likelihood. The CC should help short term.